Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (9095)	3/10/1999 11:27:00 PM
From: Bluegreen	Respond to of 17367

I'll let George do the Murphy verbatim honors. Take it away George.<g>

To: opalapril who wrote (9095)	3/10/1999 11:37:00 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

I would have to call again and I am not really sure of what he said or if I want to directly repeat it. Still sorting it out here, and if Bluegreen explains the 125 remark, I will post more right here and you will understand what he said. This is one of the values of subscribing. Even if one never knows if one can believe what he says, it is always interesting. He was very bullish on CORR and provided details I had not head elsewhere. Strange but when I have not heard it before, I assume it's correct. With XOMA and the people hours put in here and at Yahoo I wonder if he knows as much. But because he is important to any company I have to believe he can get better access and information. He said original trial was based on 125, and in essence that if they have not got to the "number" derived from original thoughts of how many would die out of 125 when there are 370 accrued Neuprex is working. No deaths in Neuprex arm, is implied thought. He said the DSMB told XOMA to start talking to the FDA. I believe he said XOMA said this in their press release. (I DON'T THINK SO) Mentioned they are accruing about 8 per week and the close bit. Said 6 then refined it to 4 weeks. Did not say much more. O.K. now tell me what opalapril means!!

To: opalapril who wrote (9095)	3/10/1999 11:54:00 PM
From: aknahow	Respond to of 17367

Bluegreen confirms what I thought. M.M. was saying the mortality target was established based on an original trial design which contemplated 125 total subjects over two years. So, IMO not M.M.s, looking at 125 the target must have been below 40, perhaps even lower. The point of Murphy was that if they now have 370 and still are not at a number reasonable people believed would be reached when 125 subjects had been accrued. (I still have doubt about the correctness of the 125 and still think it might have been 125 in just the treated arm or 250 in all). I could dig through a bunch of stuff to check it out but I am not going to.